Histamine H3 receptor as a drug discovery target

Journal of Medicinal Chemistry

Volumn 54, Issue 1, 2011, Pages 26-53

  Berlin, Michael ^a   Boyce, Christopher W ^a   De Lera Ruiz, Manuel ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 [4 [3 (4 CYCLOPROPANECARBONYLPHENOXY)PROPYL] 1 PIPERAZINYL] 1 PROPANONE; 4 (4 METHYL 3 PYRROLIDINYL) 1H IMIDAZOLE; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; 5 CYCLOHEXYL 1 [4 (4 IMIDAZOLYL) 1 PIPERIDYL] 1 PENTANONE; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; A 317920; A 320436; A 331440; A 349821; A 417022; A 687136; A 688057; A 923; ABT 834; ALPHA FLUOROMETHYLHISTIDINE; ALPHA METHYLHISTAMINE; AMPHETAMINE; ATOMOXETINE; AZELASTINE; BF 2649; BP 294; CHLORPHENIRAMINE; CIPRALISANT; CIPROXIFAN; CLOBENPROPIT; DESLORATADINE; FUB 181; FUB 407; FUB 475; FUB 649; FUB 833; FUB 836; FUB 94; GSK 207040; GSK 239512; GSK 334429; GT 2227; HISTAMINE H3 RECEPTOR; IMETIT; JB 98064; JNJ 10181457; JNJ 28583867; JNJ 5207852; JNJ 6379490; JNJ 7737782; METHYLPHENIDATE; MK 0249; MODAFINIL; N METHYLHISTAMINE; PF 03654746; RWJ 20085; SABELUZOLE; TACRINE; THIOPERAMIDE; UCL 1972; UCL 2173; UCL 2190; UNCLASSIFIED DRUG; UNINDEXED DRUG; VUF 5391; ANTIHISTAMINIC AGENT; HISTAMINE AGONIST; LIGAND;

ALLERGIC RHINITIS; ALLERGY; ALZHEIMER DISEASE; ANALGESIA; ANXIETY; ASTHMA; ATTENTION DEFICIT DISORDER; BRAIN CANCER; BRAIN ISCHEMIA; BREAST CANCER; COLON CANCER; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG TARGETING; EPILEPSY; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; IMMUNOREGULATION; INFLAMMATION; INSOMNIA; MENIERE DISEASE; MIGRAINE; MOOD DISORDER; NARCOLEPSY; NEOPLASM; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SLEEP DISORDER; SLEEP WAKING CYCLE; STROKE; TREMOR; ULCER; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG INDUSTRY; INVERSE AGONISM; ORGANIZATION AND MANAGEMENT; PHYSIOLOGY;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; DRUG INVERSE AGONISM; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; LIGANDS; PRIVATE SECTOR; RECEPTORS, HISTAMINE H3;

EID: 78651111374     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100064d     Document Type: Review

References (288)

1. 3) of histamine receptor Nature 1983, 302, 832-837
2. Golightly, L. K.; Greos, L. S. Second-generation antihistamines: actions and efficacy in the management of allergic disorders Drugs 2005, 65, 341-384
3. 2 receptor antagonist N. Engl. J. Med. 1983, 309, 1368-1373
4. Huang, J. F.; Thurmond, R. L. The new biology of histamine receptors Curr. Allergy Asthma Rep. 2008, 8, 21-27
5. 4 receptors in allergic inflammation: the search for new antihistamines Nat. Rev. Drug Discovery 2008, 7, 41-53
6. 3 receptor Mol. Pharmacol. 1999, 55, 1101-1107
7. 3 receptors Nature 1987, 327, 117-123
8. 3 receptor drugs Nat. Rev. Drug Discovery 2005, 4, 107-120 and references therein
9. 3 receptor Biochem. Pharmacol. 2007, 73, 1195-1204
10. 3 receptor heterogeneity Neuropharmacology 2003, 44, 773-786
11. Pollard, H.; Moreau, J.; Arrang, J. M.; Schwartz, J. C. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas Neuroscience 1993, 52, 169-189
12. Pillot, C.; Heron, A.; Cochois, V.; Tardivel-Lacombe, J.; Ligneau, X.; Schwartz, J. C.; Arrang, J.-M. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain Neuroscience 2002, 114, 173-193
13. Schwartz, J.-C.; Arrang, J. M.; Garbarg, M.; Pollard, H.; Ruat, M. Histaminergic transmission in the mammalian brain Physiol. Rev. 1991, 71, 1-51
14. Panula, P.; Yang, H. Y.; Costa, E. Histamine-containing neurons in the rat hypothalamus Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 2572-2576
15. Watanabe, T.; Taguchi, Y.; Shiosaka, S.; Tanaka, J.; Kubota, H.; Terano, Y.; Tohyama, M.; Wada, H. Distribution of the histaminergic neuron system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker Brain Res. 1984, 295, 13-25
16. Haas, H. L. Electrophysiology of Histamine Receptors. In The Histamine Receptor; Schwartz, J. C.; Haas, H. L., Eds.; Wiley-Liss: New York, 1992; pp 161 - 171.
17. Brown, R. E.; Stevens, D. R.; Haas, H. L. The physiology of brain histamine Prog. Neurobiol. 2001, 63, 637-672
18. 3 receptors regulate glutamate, but not GABA release in rat thalamus Neuropharmacology 2007, 52, 527-535
19. Kraus, M. M.; Fischer, H.; Tran, M. H.; Philippu, A.; Prast, H. Modulation of acetylcholine release by histamine in the nucleus accumbens Inflammation Res. 2001, 50 (Suppl. 2) S74-S75
20. Schlicker, E.; Fink, K.; Hinterthaner, M.; Goethert, M. Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 1989, 340, 633-638
21. Schlicker, E.; Fink, K.; Detzner, M.; Goethert, M. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors J. Neural Transm. 1993, 93, 1-10
22. 3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons Eur. J. Pharmacol. 2007, 563, 117-123
23. 3 receptors inhibit serotonin release in substantia nigra pars reticulata J. Neurosci. 2004, 24, 8704-8710
24. 4 receptor mediates chemotaxis and calcium mobilization of mast cells J. Pharmacol. Exp. Ther. 2003, 305, 1212-1221
25. 3 receptors J. Invest. Dermatol. 2004, 123, 116-123
26. Rozniecki, J. J.; Letourneau, R.; Sugiultzoglu, M.; Spanos, C.; Gorbach, J.; Theoharides, T. C. Differential effect of histamine 3 receptor-active agents on brain, but not peritoneal, mast cell activation J. Pharmacol. Exp. Ther. 1999, 290, 1427-1435
27. 3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction Eur. J. Pharmacol. 2004, 484, 83-89
28. 3 receptors Nature 1987, 327, 117-123
29. 3 receptor agonist J. Pharmacol. Exp. Ther. 1992, 263, 304-310
30. 3 receptor Eur. J. Med. Chem. 1992, 27, 511-517
31. 3-receptor antagonist J. Pharmacol. Exp. Ther. 1998, 287, 658-666
32. 3 receptors in vitro and in vivo Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11086-11091
33. Arrang, J.-M.; Morisset, S.; Gbahou, F. Constitutive activity of the histamine H3 receptor Trends Pharmacol. Sci. 2007, 28, 350-357
34. Greasley, P. J.; Clapham, J. C. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing? Eur. J. Pharmacol. 2006, 553, 1-9
35. 3 receptor antagonists on tele-methylhistamine levels in rat cerebral cortex Biochem. Pharmacol. 1999, 57, 1059-1066
36. 3 receptor antagonists act at a single site? Eur. J. Pharmacol. 2001, 431, 215-222
37. 3 receptor Biochem. Pharmacol. 2007, 73, 1195-1204
38. 3 histamine receptors increases the release of prolactin in male rats Neuroendocrinology 1993, 57, 654-657 as well as ref 78
39. Huang, Z.-L.; Mochizuki, T.; Qu, W.-M.; Hong, Z.-Y.; Watanabe, T.; Urade, Y.; Hayaishi, O. Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4687-4692
40. Cecchi, M.; Giorgetti, M.; Bacciottini, L.; Giovannini, M. G.; Blandina, P. Increase of acetylcholine release from cortex of freely moving rats by administration of histamine into the nucleus basalis magnocellularis Inflammation Res. 1998, 47 (Suppl. 1) S32-S33
41. 1 receptors in the nucleus basalis magnocellularis: a dual probe microdialysis study in the freely moving rat Eur. J. Neurosci. 2001, 13, 68-78
42. 3 receptor activation in rats Br. J. Pharmacol. 1996, 119, 1656-1664
43. +-evoked release of acetylcholine from rat cortex in vivo Inflammation Res. 1997, 46, S3-S4
44. 3 receptors in the rat basolateral amygdala improves expression of fear memory and enhances acetylcholine release Eur. J. Neurosci. 2002, 16, 521-528
45. 3 receptor-mediated impairment of contextual fear conditioning and in vivo inhibition of cholinergic transmission in the rat basolateral amygdala Eur. J. Neurosci. 2001, 14, 1522-1532
46. 3 receptors results in changes in brain histamine tone leading to an obese phenotype J. Clin. Invest. 2002, 110, 1791-1799
47. 3 receptors Mol. Pharmacol. 2002, 62, 389-397
48. Agnati, L. F.; Ferre, S.; Lluis, C.; Franco, R.; Fuxe, K. Molecular mechanisms and therapeutic implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons Pharmacol. Rev. 2003, 55, 509-550
49. 2 receptors and the implications for striatal function Neuropharmacology 2008, 55, 190-197
50. 2A receptor antagonists for Parkinsons disease Expert Opin. Invest. Drugs 2009, 18, 1619-1631
51. Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J. P. Histamine H3 receptor antagonists reach out for the clinic Drug Discovery Today 2005, 10, 1613-1627 and references therein
52. Investigational Drugs Database (IDdb), Thomson Pharma Partnering. http://partnering.thomson-pharma.com (accessed Aug 2009).
53. Stocking, E. M. Histamine H3 antagonists as wake-promoting and pro-cognitive agents Curr. Top. Med. Chem. 2008, 8, 988-1002 and references therein
54. Stark, H. Histamine H3-receptor agonists and antagonists: chemical, pharmacological, and clinical aspects Chem. Mol. Aspects Drug Des. Action 2008, 199, 199-214 and references therein
55. Letavic, M. A.; Barbier, A. J.; Dvorak, C. A.; Carruthers, N. I. Recent medicinal chemistry of the histamine H3 receptor Prog. Med. Chem. 2006, 44, 181-206
56. Vohora, D. Histamine-selective H3 receptor ligands and cognitive functions: an overview IDrugs 2004, 7, 667-673
57. Cowart, M.; Altenbach, R.; Black, L.; Faghih, R.; Zhao, C.; Hancock, A. A. Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists Mini-Rev. Med. Chem. 2004, 4, 979-992
58. Wijtmans, M.; Leurs, R.; de Esch, I. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas Expert Opin. Invest. Drugs 2007, 16, 967-985
59. Ramesh, V.; Thakkar, M. M.; Strecker, R. E.; Basheer, R.; McCarley, R. W. Wakefulness-inducing effects of histamine in the basal forebrain of freely moving rats Behav. Brain Res. 2004, 152, 271-278
60. White, J. M.; Rumbold, G. R. Behavioural effects of histamine and its antagonists: a review Psychopharmacology (Berlin) 1988, 95, 1-14
61. 1-Antihistamines and the central nervous system Clin. Allergy Immunol. 2002, 17, 337-388
62. Barbier, A. J.; Bradbury, M. J. Histaminergic control of sleep-wake cycles: recent therapeutic advances for sleep and wake disorders CNS Neurol. Disord.: Drug Targets 2007, 6, 31-43
63. Parmentier, R.; Anaclet, C.; Guhennec, C.; Brousseau, E.; Bricout, D.; Giboulot, T.; Bozyczko-Coyne, D.; Spiegel, K.; Ohtsu, H.; Williams, M.; Lin, J. S. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders Biochem. Pharmacol. 2007, 73, 1157-1171
64. Monti, J. M.; Jantos, H.; Ponzoni, A.; Monti, D. Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats Neuropsychopharmacology 1996, 15, 31-35
65. McLeod, R. L.; Aslanian, R.; Del Prado, M.; Duffy, R.; Egan, R. W.; Kreutner, W.; McQuade, R.; Hey, J. A. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig J. Pharmacol. Exp. Ther. 1998, 287, 43-50
66. Lamberty, Y.; Margineanu, D. G.; Dassesse, D.; Klitgaard, H. H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat Pharmacol. Res. 2003, 48, 193-198
67. Herjavecz, I.; Hirschberg, A. Histamine in Allergy. In Histamine: Biology and Medical Aspects; Falus, A., Ed.; Spring Med: Budapest, Hungary, 2004; pp 140 - 158.
68. Gelfand, E. W. Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists Am. J. Med. 2002, 113, 2S-7S
69. Gross, P.; Teasdale, G. M.; Angerson, W. J.; Harper, A. M. Characteristics of increased cerebrovascular permeability resulting from carotid arterial infusion of histamine Prog. Migraine Res. 1981, 1, 43-50
70. 1 receptors in scratching induced by histamine receptor agonists in BalbC mice Br. J. Pharmacol. 2004, 142, 374-380
71. Hossen, M. A.; Inoue, T.; Shinmei, Y.; Fujii, Y.; Watanabe, T.; Kamei, C. Role of substance P on histamine H3 antagonist-induced scratching behavior in mice J. Pharmacol. Sci. 2006, 100, 297-302
72. Yokota, E.; Kuyama, S.; Ogawa, M.; Kamei, C. Substance P is involved in the effect of histamine H3 receptor agonist, Sch 50971 on nasal allergic symptoms in mice Int. Immunopharmacol. 2008, 8, 1083-1088
73. 3 receptors Eur. J. Pharmacol. 1995, 273, 83-88
74. 3-receptors in guinea pig perfused bronchioles and lung parenchymal strips Lung 1992, 170, 95-108
75. Burgaud, J. L.; Oudart, N. Effect of an histaminergic H3 agonist on the non-adrenergic non-cholinergic contraction in guinea-pig perfused bronchioles J. Pharm. Pharmacol. 1993, 45, 955-958
76. 3-receptor for histamine: role of epithelium Br. J. Pharmacol. 1993, 109, 960-966
77. 3R pathway Biochem. Pharmacol. 2007, 73, 1146-1156
78. 3 receptors in isolated perfused rabbit lungs Eur. J. Pharmacol. 1995, 277, 243-250
79. Rouleau, A.; Garbarg, M.; Ligneau, X.; Mantion, C.; Lavie, P.; Advenier, C.; Lecomte, J.-M.; Krause, M.; Stark, H.; Schunack, W.; Schwartz, J.-C. Bioavailability and antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug J. Pharmacol. Exp. Ther. 1997, 281, 1085-1094
80. OConnor, B. J.; Lecomte, J. M.; Barnes, P. J. Effect of an inhaled histamine H3-receptor agonist on airway responses to sodium metabisulphite in asthma Br. J. Clin. Pharmacol. 1993, 35, 55-57
81. Millan-Guerrero, R. O.; Pineda-Lucatero, A. G.; Hernandez-Benjamin, T.; Tene, C. E.; Pacheco, M. F. N -Alpha-methylhistamine safety and efficacy in migraine prophylaxis: phase I and phase II studies Headache 2003, 43, 389-394
82. Millan-Guerrero, R. O.; Isais-Millan, R.; Benjamin, T.-H.; Tene, C. E. N -Alpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study Can. J. Neurol. Sci. 2006, 33, 195-199
83. Mobarakeh, J. I.; Sakurada, S.; Katsuyama, S.; Kutsuwa, M.; Kuramasu, A.; Lin, Z. Y.; Watanabe, T.; Hashimoto, Y.; Watanabe, T.; Yanai, K. Role of histamine H1 receptor in pain perception: a study of the receptor gene knockout mice Eur. J. Pharmacol. 2000, 391, 81-89
84. Yoshida, A.; Mobarakeh, J. I.; Sakurai, E.; Sakurada, S.; Orito, T.; Kuramasu, A.; Kato, M.; Yanai, K. Intrathecally-administered histamine facilitates nociception through tachykinin NK1 and histamine H1 receptors: a study in histidine decarboxylase gene knockout mice Eur. J. Pharmacol. 2005, 522, 55-62
85. Cannon, K. E.; Nalwalk, J. W.; Stadel, R.; Ge, P.; Lawson, D.; Silos-Santiago, I.; Hough, L. B. Activation of spinal histamine H3 receptors inhibits mechanical nociception Eur. J. Pharmacol. 2003, 470, 139-147
86. 3 receptors inhibits formalin-induced inflammation and nociception, respectively Pharmacol., Biochem. Behav. 2007, 88, 122-129
87. Malmberg, A. P.; Lamberti, C.; Ghelardini, C.; Giotti, A.; Bartolini, A. Role of histamine in rodent antinociception Br. J. Pharmacol. 1994, 111, 1269-1279
88. Malmberg, A. P.; Lamberti, C.; Ipponi, A.; Hanninen, J.; Gheraldini, C.; Bartolini, A. Effects of two histamine- N -methyltransferase inhibitors, SKF 91488 and BW 301 U, in rodent antinociception Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 355, 354-360
89. Kennedy, J. D. Neuropathic pain: molecular complexity underlies continuing unmet medical need J. Med. Chem. 2007, 50, 2547-2556
90. 3-receptors: a new frontier in myocardial ischemia J. Pharmacol. Exp. Ther. 2000, 292, 825-830
91. 3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release J. Pharmacol. Exp. Ther. 1994, 271, 1259-1266
92. 2-adrenoceptors Circ. Res. 1996, 78, 475-481
93. Fryer, R. M.; Reinhart, G. A.; Esbenshade, T. A. Histamine in cardiac sympathetic ganglia: a novel neurotransmitter? Mol. Interventions 2006, 6, 14-19
94. Kumar, K. V.; Krishna, D. R.; Palit, G. Histaminergic H1 receptors mediate l -histidine-induced anxiety in elevated plus-maze test in mice Behav. Pharmacol. 2007, 18, 213-217
95. Esbenshade, T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.; Brioni, J. D. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders Br. J. Pharmacol. 2008, 154, 1166-1181
96. 3 receptor antagonists go to clinics Biol. Pharm. Bull. 2008, 31, 2163-2181
97. Hudkins, R. L.; Raddatz, R. Recent advances in drug discovery of histamine H3 antagonists Annu. Rep. Med. Chem. 2007, 42, 49-62
98. Esbenshade, T. A.; Fox, G. B.; Cowart, M. D. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders Mol. Interventions 2006, 6, 77-88
99. Witkin, J. M.; Nelson, D. L. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system Pharmacol.Ther. 2004, 103, 1-20 and references therein
100. Vohora, D.; Pal, S. N.; Pillai, K. K. Histaminergic H3-receptors as modulators of CNS function Indian J. Pharmacol. 2001, 33, 17-28
101. Hancock, A. A. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists Biochem. Pharmacol. 2006, 71, 1103-1113
102. Petroianu, G.; Arafat, K.; Sasse, B. C.; Stark, H. Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents Pharmazie 2006, 61, 179-182
103. Apelt, J.; Ligneau, X.; Pertz, H. H.; Arrang, J.-M.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W.; Stark, H. Development of a new class of nonimidazole histamine H3 receptor ligands with combined inhibitory histamine N -methyltransferase activity J. Med. Chem. 2002, 45, 1128-1141
104. 3 receptor antagonists, using the newly developed molecular modeling program SLATE J. Med. Chem. 2001, 44, 1666-1674
105. Uveges, A. J.; Kowal, D.; Zhang, Y.; Spangler, T. B.; Dunlop, J.; Semus, S.; Jones, P. G. The role of transmembrane helix 5 in agonist binding to the human H3 receptor J. Pharmacol. Exp. Ther. 2002, 301, 451-458
106. 3R) binding pocket suitable for virtual drug design Inflammation Res. 2005, 54 (Suppl. 1) S50-S51
107. Arrang, J.-M. Histamine and schizophrenia Int. Rev. Neurobiol. 2007, 78, 247-287
108. 11C]pyrilamine and positron emission tomography J. Neurochem. 1992, 59, 128-136
109. Alvarez, E. O. The role of histamine on cognition Behav. Brain Res. 2009, 199, 183-189 and references therein
110. Philippu, A.; Prast, H. Importance of histamine in modulatory processes, locomotion and memory Behav. Brain Res. 2001, 124, 151-159 and references therein
111. Yanai, K.; Dai, H.; Sakurai, E.; Watanabe, T. The roles of histamine H1 receptors on cognition Inflammation Res. 2008, 57 (Suppl. 1) S39-S40
112. Zlomuzica, A.; Ruocco, L. A.; Sadile, A. G.; Huston, J. P.; Dere, E. Histamine H1 receptor knockout mice exhibit impaired spatial memory in the eight-arm radial maze Br. J. Pharmacol. 2009, 157, 86-91
113. Terry, A. V. Role of the central cholinergic system in the therapeutics of schizophrenia Curr. Neuropharmacol. 2008, 6, 286-292
114. Laruelle, M.; Frankle, W. G.; Narendran, R.; Kegeles, L. S.; Abi-Dargham, A. Mechanism of action of antipsychotic drugs: from dopamine D2 receptor antagonism to glutamate NMDA facilitation Clin. Ther. 2005, 27 (Suppl. 1) S16-S24
115. Prince, J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder J. Clin. Psychopharmacol. 2008, 28 (Suppl. 2) S39-S45 and references therein
116. Biederman, J.; Spencer, T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder Biol. Psychiatry 1999, 46, 1234-1242
117. Horner, W. E.; Johnson, D. E.; Schmidt, A. E.; Rollema, H. Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex Eur. J. Pharmacol. 2007, 558, 96-97
118. Raminder, K. Approved and investigational uses of modafinil: an evidence-based review Drugs 2008, 68, 1803-1839
119. Minzenberg, M. J.; Carter, C. S. Modafinil: a review of neurochemical actions and effects on cognition Neuropsychopharmacology 2008, 33, 1477-1502
120. 2-generated lipid mediators in the brain: the good, the bad and the ugly Neuroscientist 2006, 12, 245-260
121. Tedford, C. E.; Yates, S. L.; Pawlowski, G. P.; Nalwalk, J. W.; Hough, L. B.; Amin, K. M.; Phillips, J. G.; Durant, G. J.; Frederickson, R. C. A. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies J. Pharmacol. Exp. Ther. 1995, 275, 598-604
122. Giovannini, M. G.; Bartolini, L.; Bacciottini, L.; Greco, L.; Blandina, P. Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia Behav. Brain Res. 1999, 104, 147-155
123. Komater, V. A.; Buckley, M. J.; Browman, K. E.; Pan, J. B.; Hancock, A. A.; Decker, M. W.; Fox, G. B. Effects of histamine H3 receptor antagonists in two models of spatial learning Behav. Brain Res. 2005, 159, 295-300
124. Komater, V. A.; Browman, K. E.; Curzon, P.; Hancock, A. A.; Decker, M. W.; Fox, G. B. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization Psychopharmacology 2003, 167, 363-372
125. Blandina, P.; Efoudebe, M.; Cenni, G.; Mannaioni, P.; Passani, M. B. Acetylcholine, histamine, and cognition: two sides of the same coin Learn. Mem. 2004, 11, 1-8 and references therein
126. Giovannini, M. G.; Efoudebe, M.; Passani, M. B.; Baldi, E.; Bucherelli, C.; Giachi, F.; Corradetti, R.; Blandina, P. Improvement in fear memory by histamine-elicited ERK2 activation in hippocampal CA3 cells J. Neurosci. 2003, 23, 9016-9023
127. Akhtar, M.; Devi, P. U.; Ali, A.; Pillai, K. K.; Vohora, D. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice Fundam. Clin. Pharmacol. 2006, 20, 373-378
128. Jia, F.; Kato, M.; Dai, H.; Xu, A.; Okuda, T.; Sakurai, E.; Okamura, N.; Lovenberg, T. W.; Barbier, A.; Carruthers, N. I.; Iinuma, K.; Yanai, K. Effects of histamine H3 antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice Neuropharmacology 2006, 50, 404-411
129. Gemkow, M. J.; Davenport, A. J.; Harich, S.; Ellenbroek, B. A.; Cesura, A.; Hallett, D. The histamine H3 receptor as a therapeutic drug target for CNS disorders Drug Discovery Today 2009, 14, 509-515
130. Ali, S. M.; Tedford, C. E.; Gregory, R.; Handley, M. K.; Yates, S. L.; Hirth, W. W.; Phillips, J. G. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists J. Med. Chem. 1999, 42, 903-909
131. Liu, H.; Kerdesky, F. A.; Black, L. A.; Fitzgerald, M.; Henry, R.; Esbenshade, T. A.; Hancock, A. A.; Bennani, Y. L. An efficient multigram synthesis of the potent histamine H3 antagonist GT-2331 and the reassessment of the absolute configuration J. Org. Chem. 2004, 69, 192-194
132. Ito, S.; Yoshimoto, R.; Miyamoto, Y.; Mitobe, Y.; Nakamura, T.; Ishihara, A.; MacNeil, D. J.; Kanatani, A.; Tokita, S. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor Eur. J. Pharmacol. 2006, 529, 40-46
133. Stark, H; Huls, A; Ligneau, X; Purand, K.; Pertz, H; Arrang, J. M.; Schwartz, J. C.; Schunack, W. Development of FUB 181, a selective histamine H3-receptor antagonist of high oral in vivo potency with 4-(omega-(arylalkyloxy) alkyl)-1 H -imidazole structure Arch. Pharm. 1998, 331, 211-218
134. Meier, G.; Ligneau, X.; Pertz, H. H.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W.; Stark, H. Piperidino-hydrocarbon compounds as novel non-imidazole histamine H3-receptor antagonists Bioorg. Med. Chem. 2002, 10, 2535-2542
135. Ligneau, X.; Perrin, D.; Landais, L.; Camelin, J.-C.; Calmels, T. P. G.; Berrebi-Bertrand, I.; Lecomte, J.-M.; Parmentier, R.; Anaclet, C.; Lin, J.-S.; Bertaina-Anglade, V.; la Rochelle, C. Drieu; dAniello, F.; Rouleau, A.; Gbahou, F.; Arrang, J.-M.; Ganellin, C. R.; Stark, H.; Schunack, W.; Schwartz, J.-C. BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology J. Pharmacol. Exp. Ther. 2007, 320, 365-375
136. www.clinicaltrials.gov. For a detailed list of clinical trials discussed in this review see the Supporting Information.
137. Vasudevan, A.; Conner, S. E.; Gentles, R. G.; Faghih, R.; Liu, H.; Dwight, W.; Ireland, L.; Kang, C. H.; Esbenshade, T. A.; Bennani, Y. L.; Hancock, A. A. Synthesis and evaluation of potent pyrrolidine H3 antagonists Bioorg. Med. Chem. Lett. 2002, 12, 3055-3058
138. Fox, G. B.; Pan, J. B.; Radek, R. J.; Lewis, A. M.; Bitner, R. S.; Esbenshade, T. A.; Faghih, R.; Bennani, Y. L.; Williams, M.; Yao, B. B.; Decker, M. W.; Hancock, A. A. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization J. Pharmacol. Exp. Ther. 2003, 305, 897-908 (Pubitemid 36617966)
139. Faghih, R.; Dwight, W.; Black, L.; Liu, H.; Gentles, R.; Phelan, K.; Esbenshade, T. A.; Ireland, L.; Miller, T. R.; Kang, C.-H.; Krueger, K. M.; Fox, G. B.; Hancock, A. A.; Bennani, Y. L. Structure-activity relationships of non-imidazole H3 receptor ligands. Part 2: Binding preference for d -amino acids motifs Bioorg. Med. Chem. Lett. 2002, 12, 2035-2037
140. Curtis, M. P.; Dwight, W.; Pratt, J.; Cowart, M.; Esbenshade, T. A.; Krueger, K. M.; Fox, G. B.; Pan, J. B.; Pagano, T. G.; Hancock, A. A.; Faghih, R.; Bennani, Y. L. d -Amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H3-receptor antagonist Arch. Pharm. 2004, 337, 219-229
141. Esbenshade, T. A.; Fox, G. B.; Krueger, K. M.; Baranowski, J. L.; Miller, T. R.; Kang, C. H.; Denny, L. I.; Witte, D. G.; Yao, B. B.; Pan, J. B.; Faghih, R.; Bennani, Y. L.; Williams, M.; Hancock, A. A. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist Biochem. Pharmacol. 2004, 68, 933-945
142. Cowart, M.; Faghih, R.; Curtis, M. P.; Gfesser, G. A.; Bennani, Y. L.; Black, L. A.; Pan, L.; Marsh, K. C.; Sullivan, J. P.; Esbenshade, T. A.; Fox, G. B.; Hancock, A. A. 4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl) benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention J. Med. Chem. 2005, 48, 38-55
143. Esbenshade, T. A.; Fox, G. B.; Krueger, K. M.; Miller, T. R.; Kang, C. H.; Denny, L. I.; Witte, D. G.; Yao, B. B.; Pan, L.; Wetter, J.; Marsh, K.; Bennani, Y. L.; Cowart, M. D.; Sullivan, J. P.; Hancock, A. A. Pharmacological properties of ABT-239 [4-(2-{2-[(2 R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5- yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties J. Pharmacol. Exp. Ther. 2005, 313, 165-175
144. Fox, G. B.; Esbenshade, T. A.; Pan, J. B.; Radek, R. J.; Krueger, K. M.; Yao, B. B.; Browman, K. E.; Buckley, M. J.; Ballard, M. E.; Komater, V. A.; Miner, H.; Zhang, M.; Faghih, R.; Rueter, L. E.; Bitner, R. S.; Drescher, K. U.; Wetter, J.; Marsh, K.; Lemaire, M.; Porsolt, R. D.; Bennani, Y. L.; Sullivan, J. P.; Cowart, M. D.; Decker, M. W.; Hancock, A. A. Pharmacological properties of ABT-239 [4-(2-{2-[(2 R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl) benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist J. Pharmacol. Exp. Ther. 2005, 313, 176-190
145. Ku, Y.-Y.; Pu, Y.-M.; Grieme, T.; Sharma, P.; Bhatia, A. V.; Cowart, M. An efficient and convergent synthesis of the potent and selective H3 antagonist ABT-239 Tetrahedron 2006, 62, 4584-4589
146. Cowart, M.; Gfesser, G. A.; Browman, K. E.; Faghih, R.; Miller, T. R.; Milicic, I.; Baranowski, J. L.; Krueger, K. M.; Witte, D. G.; Molesky, A. L.; Komater, V. A.; Buckley, M. J.; Diaz, G. J.; Gagne, G. D.; Zhou, D.; Deng, X.; Pan, L.; Roberts, E. M.; Diehl, M. S.; Wetter, J. M.; Marsh, K. C.; Fox, G. B.; Brioni, J. D.; Esbenshade, T. A.; Hancock, A. A. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity Biochem. Pharmacol. 2007, 73, 1243-1255
147. Gfesser, G. A.; Faghih, R.; Bennani, Y. L.; Curtis, M. P.; Esbenshade, T. A.; Hancock, A. A.; Cowart, M. D. Structure-activity relationships of arylbenzofuran H3 receptor antagonists Bioorg. Med. Chem. Lett. 2005, 15, 2559-2563
148. Altenbach, R. J.; Liu, H.; Banfor, P. N.; Browman, K. E.; Fox, G. B.; Fryer, R. M.; Komater, V. A.; Krueger, K. M.; Marsh, K.; Miller, T. R.; Pan, J. B.; Pan, L.; Sun, M.; Thiffault, C.; Wetter, J.; Zhao, C.; Zhou, D.; Esbenshade, T. A.; Hancock, A. A.; Cowart, M. D. Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists J. Med. Chem. 2007, 50, 5439-5448
149. Black, L. A.; Nersesian, D. L.; Sharma, P.; Ku, Y.-Y.; Bennani, Y. L.; Marsh, K. C.; Miller, T. R.; Esbenshade, T. A.; Hancock, A. A.; Cowart, M. 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration Bioorg. Med. Chem. Lett. 2007, 17, 1443-1446
150. Black, L. A.; Liu, H.; Diaz, G. J.; Fox, G. B.; Browman, K. E.; Wetter, J.; Marsh, K. C.; Miller, T. R.; Esbenshade, T. A.; Brioni, J.; Cowart, M. D. Minimization of potential hERG liability in histamine H3 receptor antagonists Inflammation Res. 2008, 57, S45-S46
151. Pu, Y.-M.; Ku, Y.-Y.; Grieme, T.; Black, L. A.; Bhatia, A. V.; Cowart, M. An expedient and multikilogram synthesis of a naphthalenoid H3 antagonist Org. Process Res. Dev 2007, 11, 1004-1009
152. Zhao, C.; Sun, M.; Bennani, Y. L.; Gopalakrishnan, S. M.; Witte, D. G.; Miller, T. R.; Krueger, K. M.; Browman, K. E.; Thiffault, C.; Wetter, J.; Marsh, K. C.; Hancock, A. A.; Esbenshade, T. A.; Cowart, M. D. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists J. Med. Chem. 2008, 51, 5423-5430
153. Medhurst, A. D.; Atkins, A. R.; Beresford, I. J.; Brackenborough, K.; Briggs, M. A.; Calver, A. R.; Cilia, J.; Cluderay, J. E.; Crook, B.; Davis, J. B.; Davis, R. K.; Davis, R. P.; Dawson, L. A.; Foley, A. G.; Gartlon, J.; Gonzalez, M. I.; Heslop, T.; Hirst, W. D.; Jennings, C.; Jones, D. N. C.; Lacroix, L. P.; Martyn, A.; Ociepka, S.; Ray, A.; Regan, C. M.; Roberts, J. C.; Schogger, J.; Southam, E.; Stean, T. O.; Trail, B. K.; Upton, N.; Wadsworth, G.; Wald, J. A.; White, T.; Witherington, J.; Woolley, M. L.; Worby, A.; Wilson, D. M. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimers disease brain and improves cognitive performance in preclinical models J. Pharmacol. Exp. Ther. 2007, 321, 1032-1045
154. Medhurst, A. D.; Briggs, M. A.; Bruton, G.; Calver, A. R.; Chessell, I.; Crook, B.; Davis, J. B.; Davis, R. P.; Foley, A. G.; Heslop, T.; Hirst, W. D.; Medhurst, S. J.; Ociepka, S.; Ray, A.; Regan, C. M.; Sargent, B.; Schogger, J.; Stean, T. O.; Trail, B. K.; Upton, N.; White, T.; Orlek, B.; Wilson, D. M. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats Biochem. Pharmacol. 2007, 73, 1182-1194
155. Southam, E.; Cilia, J.; Gartlon, J. E.; Woolley, M. L.; Lacroix, L. P.; Jennings, C. A.; Cluderay, J. E.; Reavill, C.; Rourke, C.; Wilson, D. M.; Dawson, L. A.; Medhurst, A. D.; Jones, D. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040 Psychopharmacology 2009, 201, 483-494
156. Nagase, T.; Mizutani, T.; Ishikawa, S.; Sekino, E. O.; Sasaki, T.; Fujimura, T.; Ito, S.; Mitobe, Y.; Miyamoto, Y.; Yoshimoto, R.; Tanaka, T.; Ishihara, A.; Takenaga, N.; Tokita, S.; Fukami, T.; Sato, N. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists J. Med. Chem. 2008, 51, 4780-4789
157. Nagase, T.; Mizutani, T.; Sekino, E.; Ishikawa, S.; Ito, S.; Mitobe, Y.; Miyamoto, Y.; Yoshimoto, R.; Tanaka, T.; Ishihara, A.; Takenaga, N.; Tokita, S.; Sato, N. Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists J. Med. Chem. 2008, 51, 6889-6901
158. Nagase, T.; Sato, N.; Kii, S.; Sato, K.; Tsuritani, T.; Sawada, N. Process for Production of 4(3 H)-Quinazolinone Derivative. PCT Int. Appl. WO 2006132424, 2006.
159. Mizutani, T.; Nagase, T.; Ito, S.; Miyamoto, Y.; Tanaka, T.; Takenaga, N.; Tokita, S.; Sato, N. Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3 H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists Bioorg. Med. Chem. Lett. 2008, 18, 6041-6045
160. Wager, T. T. Physicochemical Properties Approach to the Identification of a Histamine H3 Receptor Antagonist for the Treatment of ADHD. Abstracts of Papers, 237th National Meeting of the American Chemical Society, Salt Lake City, UT, Mar 22-26, 2009; American Chemical Society: Washington, DC, 2009.
161. Wager, T. T.; Chandrasekaran, R. Y.; Butler, T. W. Preparation of Pyrrolidinylmethylphenylcyclobutanecarboxamides as Histamine H3 Receptor Antagonists. PCT Int. Appl. WO 2007049123, 2007.
162. Bembenek, S. D.; Keith, J. M.; Letavic, M. A.; Apodaca, R. D.; Barbier, A. J.; Dvorak, L.; Aluisio, L.; Miller, K. L.; Lovenberg, T. W.; Carruthers, N. I. Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling Bioorg. Med. Chem. 2008, 16, 2968-2973
163. Morini, G.; Comini, M.; Rivara, M.; Rivara, S.; Bordi, F.; Plazzi, P. V.; Flammini, L.; Saccani, F.; Bertoni, S.; Ballabeni, V.; Barocelli, E.; Mor, M. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity Bioorg. Med. Chem. 2008, 16, 9911-9924
164. Hey, J. A.; Aslanian, R. G. Use of Dual H3 /M2 Antagonists in the Treatment of Cognition Deficit Disorders. PCT Int. Appl.WO 2002072093, 2002.
165. Jones, B. E. From waking to sleeping: neuronal and chemical substrates Trends Pharmacol. Sci. 2005, 26, 578-586
166. Krueger, J. M.; Rector, D. M.; Roy, S.; Van Dongen, H. P. A.; Belenky, G.; Panksepp, J. Sleep as a fundamental property of neuronal assemblies Nat. Rev. Neurosci. 2008, 9, 910-919
167. Soya, A.; Song, Y. H.; Kodama, T.; Honda, Y.; Fujiki, N.; Nishino, S. CSF histamine levels in rats reflect the central histamine neurotransmission Neurosci. Lett. 2008, 430, 224-229 and references therein
168. Mignot, E. Narcolepsy: Pharmacology, Pathophysiology and Genetics. In Principles and Practice of Sleep Medicine; Kryger, M. H.; Roth, T.; Dement, W. C., Eds.; Elsevier Saunders: Philadelphia, PA, 2005; pp 761 - 779.
169. Passani, M. B.; Lin, J.-S.; Hancock, A.; Crochet, S.; Blandina, P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders Trends Pharmacol. Sci. 2004, 25, 618-625
170. Bonaventure, P.; Letavic, M.; Dugovic, C.; Wilson, S.; Aluisio, L.; Pudiak, C.; Lord, B.; Mazur, C.; Kamme, F.; Nishino, S.; Carruthers, N.; Lovenberg, T. Histamine H3 receptor antagonists: from target identification to drug leads Biochem. Pharmacol. 2007, 73, 1084-1096
171. Lin, J.-S.; Dauvilliers, Y.; Arnulf, I.; Bastuji, H.; Anaclet, C.; Parmentier, R.; Kocher, L.; Yanagisawa, M.; Lehert, P.; Ligneau, X.; Perrin, D.; Robert, P.; Roux, M.; Lecomte, J.-M.; Schwartz, J.-C. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin-/- mice and patients Neurobiol. Dis. 2008, 30, 74-83
172. Raga, M. M.; Sallares, J.; Guerrero, M.; Guglietta, A. Preparation of 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine Monohydrochloride as a Histamine H3 Receptor Ligand. PCT Int. Appl. WO 2006084833, 2006.
173. Guo, R. X.; Anaclet, C.; Roberts, J. C.; Parmentier, R.; Zhang, M.; Guidon, G.; Buda, C.; Sastre, J. P.; Feng, J. Q.; Franco, P.; Brown, S. H.; Upton, N.; Medhurst, A. D.; Lin, J. S. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice Br. J. Pharmacol. 2009, 157, 104-117
174. Le, S.; Gruner, J. A.; Mathiasen, J. R.; Marino, M. J.; Schaffhauser, H. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists J. Pharmacol. Exp. Ther. 2008, 325, 902-909
175. Shah, C.; McAtee, L.; Breitenbucher, J. G.; Rudolph, D.; Li, X.; Lovenberg, T. W.; Mazur, C.; Wilson, S. J.; Carruthers, N. I. Novel human histamine H3 receptor antagonists Bioorg. Med. Chem. Lett. 2002, 12, 3309-3312
176. Apodaca, R.; Dvorak, C. A.; Xiao, W.; Barbier, A. J.; Boggs, J. D.; Wilson, S. J.; Lovenberg, T. W.; Carruthers, N. I. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines J. Med. Chem. 2003, 46, 3938-3944
177. Barbier, A. J.; Berridge, C.; Dugovic, C.; Laposky, A. D.; Wilson, S. J.; Boggs, J.; Aluisio, L.; Lord, B.; Mazur, C.; Pudiak, C. M.; Langlois, X.; Xiao, W.; Apodaca, R.; Carruthers, N. I.; Lovenberg, T. W. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist Br. J. Pharmacol. 2004, 143, 649-661
178. Dvorak, C. A.; Apodaca, R.; Barbier, A. J.; Berridge, C. W.; Wilson, S. J.; Boggs, J. D.; Xiao, W.; Lovenberg, T. W.; Carruthers, N. I. 4-Phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists J. Med. Chem. 2005, 48, 2229-2238
179. Fujiki, N.; Yoshino, F.; Lovenberg, T. W.; Nishino, S. Wake promoting effects of non-imidazoline histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice Sleep (Sleep Res. Soc. Meet.) 2006, 29 A230
180. Galici, R.; Boggs, J. D.; Aluisio, L.; Fraser, I. C.; Bonaventure, P.; Lord, B.; Lovenberg, T. W. JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition Neuropharmacology 2009, 56, 1131-1137
181. Mani, N. S.; Jablonowski, J. A.; Jones, T. K. A scalable synthesis of a histamine H3 receptor antagonist J. Org. Chem. 2004, 69, 8115-8117
182. Nagase, T.; Sato, N.; Kanatani, A.; Tokita, S. Preparation of a 4(3 H)-Quinazolinone Compound as Histamine H3 Receptor Antagonist or Inverse Agonist. PCT Int. Appl. WO 2006085692, 2006.
183. Dunlop, B. W.; Crits-Christoph, P.; Evans, D. L.; Hirschowitz, J.; Solvason, H. B.; Rickels, K.; Garlow, S. J.; Gallop, R. J.; Ninan, P. T. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study J. Clin. Psychopharmacol. 2007, 27, 614-619
184. Imeri, L.; Opp, M. R. How (and why) the immune system makes us sleep Nat. Rev. Neurosci. 2009, 10, 199-210
185. Barbier, A. J.; Aluisio, L.; Lord, B.; Qu, Y.; Wilson, S. J.; Boggs, J. D.; Bonaventure, P.; Miller, K.; Fraser, I.; Dvorak, L.; Pudiak, C.; Dugovic, C.; Shelton, J.; Mazur, C.; Letavic, M. A.; Carruthers, N. I.; Lovenberg, T. W. Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor Eur. J. Pharmacol. 2007, 576, 43-54
186. Letavic, M. A.; Keith, J. M.; Jablonowski, J. A.; Stocking, E. M.; Gomez, L. A.; Ly, K. S.; Miller, J. M.; Barbier, A. J.; Bonaventure, P.; Boggs, J. D.; Wilson, S. J.; Miller, K. L.; Lord, B.; McAllister, H. M.; Tognarelli, D. J.; Wu, J.; Abad, M. C.; Schubert, C.; Lovenberg, T. W.; Carruthers, N. I. Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 1047-1051 (Pubitemid 46177610)
187. Smith, F. M.; Haskelberg, H.; Tracey, D. J.; Moalem-Taylor, G. Role of histamine H3 and H4 receptors in mechanical hyperalgesia following peripheral nerve injury NeuroImmunoModulation 2007, 14, 317-325
188. Lim, H.; van Rijn, R.; Ling, P.; Bakker, R.; Thurmond, R.; Leurs, R. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist J. Pharmacol. Exp. Ther. 2005, 314, 1310-1321
189. Owen, S. M.; Sturman, G.; Freeman, P. Modulation of morphine-induced antinociception in mice by histamine H3-receptor ligands Agents Actions 1994, 41, C62-C63
190. Farzin, D.; Asghari, L.; Nowrouzi, M. Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists Pharmacol., Biochem. Behav. 2002, 72, 751-760
191. Huang, L.; Adachi, N.; Nagaro, T.; Liu, K.; Arai, T. Histaminergic involvement in neuropathic pain produced by partial ligation of the sciatic nerve in rats Reg. Anesth. Pain Med. 2007, 32, 124-129
192. Medhurst, S. J.; Collins, S. D.; Billinton, A.; Bingham, S.; Dalziel, R. G.; Brass, A.; Roberts, J. C.; Medhurst, A. D.; Chessell, I. P. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain Pain 2008, 138, 61-69
193. Sindrup, S. H.; Otto, M.; Finnerup, N. B.; Jensen, T. S. Antidepressants in the treatment of neuropathic pain Basic Clin. Pharmacol. Toxicol. 2005, 96, 399-409
194. Yokoyama, H; Iinuma, K; Yanai, K; Watanabe, T; Sakurai, E; Onodera, K. Proconvulsant effect of ketotifen, a histamine H1 antagonist, confirmed by the use of d -chlorpheniramine with monitoring electroencephalography Methods Find. Exp. Clin. Pharmacol. 1993, 15, 183-188
195. Vohora, D.; Pal, S. N.; Pillai, K. K. Histamine as an anticonvulsant inhibitory neurotransmitter Curr. Neuropharmacol. 2004, 2, 419-425
196. Crowley, V.; Yeo, G.; ORahilly, S. Obesity therapy: altering the energy intake-and-expenditure balance sheet Nat. Rev. Drug Discovery 2002, 1, 276-286
197. Clineschmidt, B. V.; Lotti, V. J. Histamine: intraventricular injection suppresses ingestive behavior of the cat Arch. Int. Pharmacodyn. Ther. 1973, 206, 288-298
198. Itowi, N.; Nagai, K.; Nakagawa, H.; Watanabe, T.; Wada, H. Changes in the feeding behavior of rats elicited by histamine infussion Physiol. Behav. 1998, 44, 221-226
199. Lecklin, A.; Etu-Seppala, P.; Stark, H.; Tuomisto, L. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats Brain Res. 1998, 793, 279-288
200. Sheiner, J. B.; Morris, P.; Anderson, G. H. Food intake suppression by histidine Pharmacol., Biochem. Behav. 1985, 23, 721-726
201. Lecklin, A.; Tuomisto, L.; McDonald, E. Metoprine, an inhibitor of histamine N -methyl transferase but not cathecol- O -methyl transferase, suppresses feeding in sated and in food deprived rats Methods Find. Exp. Clin. Pharmacol. 1995, 17, 47-52
202. Orthen-Gambill, N.; Salomon, M. FMH-induced decrease in central histamine levels produced increased feeding and body weight in rats Physiol. Behav. 1992, 51, 891-893
203. Sakata, T.; Ookuma, K.; Fukagawa, K.; Fujimoto, K.; Yoshimatsu, H.; Shiraishi, T.; Wada, H. Blockade of the histamine H1 receptor in the rat ventromedial hypothalamus and feeding elicitation Brain Res. 1988, 441, 403-407 (Pubitemid 18059993)
204. Baptista, T.; Zarate, J.; Joober, R.; Colasante, C.; Beaulieu, S.; Paez, X.; Hernandez, L. Drug induced weigh gain, an impediment to successful pharmacotherapy: focus on antipsychotics Curr. Drug Targets 2004, 5, 279-299
205. Ookuma, K.; Sakata, T.; Fujimoto, K. Evidence for feeding elicited through antihistaminergic effects of tricyclic antidepressants in the rat hypothalamus Psychopharmacology 1990, 101, 481-485
206. Richelson, E.; Souder, T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds Life Sci. 2000, 68, 29-39
207. Horak, F.; Subner, U. P. Comparative tolerability of second generation antihistamines Drug Saf. 1999, 20, 385-401
208. Masaki, T.; Yoshimatsu, H.; Chiba, S.; Watanabe, T.; Sakata, T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice Diabetes 2001, 50, 385-391
209. Jorgensen, E. A.; Vogelsang, T. A.; Knigge, U. Increased susceptibility to diet-induced obesity in histamine-deficient mice Neuroendocrinology 2006, 83, 289-294
210. See for example: Pan, J.; Yao, B.; Miller, T.; Kroeger, P.; Bennani, Y.; Komater, V.; Esbenshade, T.; Hancock, A.; Decker, M.; Fox, G. Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121 Life Sci. 2006, 79, 1366-1379
211. Leurs, R.; Smit, M.; Bast, A.; Timmerman, H. Homologous histamine H1 receptor desensitization results in reduction of H1 receptor agonist efficacy Eur. J. Pharmacol. 1991, 196, 319-322
212. Hancock, A. A.; Brune, M. E. Assessment of pharmacology and potential antiobesity properties of H3 receptor antagonists/inverse agonists Expert Opin. Drugs 2005, 14, 223-241
213. Sakata, T.; Kazuyoshi, O.; Fujimoto, K.; Fukagawa, K.; Yoshimatsu, H. Histaminergic control of energy balance in rats Brain Res. Bull. 1991, 27, 371-375
214. Yoshimoto, R.; Miyamoto, Y.; Shimamura, K.; Ishihara, A.; Takahashi, K.; Kotani, H.; Chen, A. S.; Chen, H. Y.; MacNeil, D. J.; Kanatani, A.; Tokita, S. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellits Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13866-13871
215. Tokita, S. Histamine H3 Receptor as a Potential Target for Metabolic Disorders. Presented at the 3rd Modern Drug Discovery and Development Summit, San Francisco, CA, November 28-30, 2007.
216. Puigserver, P.; Wu, Z.; Park, C. W.; Graves, R.; Wright, M.; Spiegelman, B. M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis Cell 1998, 92, 829-839
217. Weyer, C.; Gautier, J. F.; Danforth, E. Development of β3-adrenoceptor agonists for the treatment of obesity and diabetes-an update Diabetes Metab. 1999, 25, 11-21
218. Sandoval, D. A.; Obici, S.; Seeley, R. J. Targeting the CNS to treat type 2 diabetes Nat. Rev. Drug Discovery 2009, 8, 386-398 and references therein
219. Masaki, T.; Yoshimatsu, H.; Chiba, S.; Watanabe, T.; Sakata, T. Central infusion of histamine reduces fat accumulation and up-regulates UCP family in leptin resistant obese mice Diabetes 2001, 50, 376-384
220. Fumihiko, H.; Ichiro, N. Diabetes Model Mouse. Jpn. Pat. Appl. JP 2004065181, 2004.
221. Yamamoto, Y.; Ishino, F.; Kaneko-Ishino, T.; Shiura, H.; Uchio-Yamada, K.; Matsuda, J.; Suzuki, O.; Sato, K. Type 2 diabetes mellitus in a non-obese mouse model induced by Meg1/Grb10 overexpression Exp. Anim. 2008, 57, 385-395
222. Masaki, T.; Yoshimatsu, H. Neuronal histamine and its receptors in obesity and diabetes Curr. Diabetes Rev. 2007, 3, 212-216 (Pubitemid 47244067)
223. Moniri, N. H.; Covington-Strachan, D.; Booth, R. G. Ligand-directed functional heterogeneityof histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling J. Pharmacol. Exp. Ther. 2004, 311, 274-281 and references therein
224. Arrang, J. M.; Garbarg, M.; Quach, T. T. Actions of betahistine at histamine receptors in the brain Eur. J. Pharmacol. 1985, 111, 73-84
225. Fossati, A.; Barone, D.; Benvenuti, C. Binding affinity profile of betahistine and its metabolites for central histamine receptors of rodents Pharmacol. Res. 2001, 43, 389-392
226. Rossi, R. Effect of the H1-histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats Physiol. Behav. 1999, 66, 517-521
227. Szelag, A. Betahistine inhibits food intake in rats Pol. J. Pharmacol. 1999, 53, 701-707
228. Barak, N.; Greenway, F. L.; Fujioka, K.; Aronne, L. J.; Kushner, R. F. Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial Int. J. Obes. 2008, 32, 1559-1565
229. Hancock, A. A.; Bennani, Y. L.; Bush, E. N.; Esbenshade, T. A.; Faghih, R.; Fox, G. B.; Jacobson, P.; Knourek-Segel, V.; Krueger, K. M.; Nuss, M. E.; Pan, J. B.; Shapiro, R.; Witte, D. G.; Yao, B. B. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist Eur. J. Pharmacol. 2004, 487, 183-197
230. Hancock, A. A.; Diehl, M. S.; Fey, T. A.; Bush, E. N.; Faghih, R.; Miller, T. R.; Krueger, K. M.; Pratt, J. K.; Cowart, M. D.; Dickinson, R. W.; Shapiro, R.; Knourek-Segel, V. E.; Droz, B. A.; McDowell, C. A.; Krishna, G.; Brune, M. E.; Esbenshade, T. A.; Jacobson, P. B. Antiobesity evaluation of histamine H3 receptor antagonist analogs of A-331440 with improved safety and efficacy Inflammation Res. 2005, 54 (Suppl. 1) S27-S29
231. Zaragoza, F.; Stephensen, H.; Knudsen, S. M.; Pridal, L.; Wulff, B. S.; Rimvall, K. 1-Alkyl-4-acylpiperazines as a new class of imidazole-free histamine H3 antagonists J. Med. Chem. 2004, 47, 2833-2838
232. Malmlof, K.; Zaragoza, F.; Golozoubova, V.; Refsgaard, H. H. F.; Cremers, T.; Raun, K.; Wulff, B. S.; Johansen, P. B.; Westerink, B.; Rimvall, K. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight Int. J. Obes. 2005, 29, 1402-1412
233. Peschke, B.; Bak, S.; Hohlweg, R.; Petterson, I.; Refsgaard, H. H. F.; Viuff, D.; Rimvall, K. Cinnamic amides of (S)-2-(aminomethyl)pyrrolidines are potent H3 antagonists Bioorg. Med. Chem. Lett. 2004, 12, 2603-2616
234. Malmlof, K.; Golozoubova, V.; Peschke, B.; Wulff, B. S.; Refsgaard, H. H. F.; Johansen, P. B.; Cremers, T.; Rimvall, K. Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides Obesity 2006, 14, 2154-2162
235. Malmlof, K.; Hastrup, S.; Wulff, B. S.; Hansen, B. C.; Peschke, B.; Jeppesen, C. B.; Hohlweg, R.; Rimvall, K. Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species Biochem. Pharmacol. 2007, 73, 1237-1242
236. Holgate, S. T.; Polosa, R. Treatment strategies for allergies and asthma Nat. Rev. Immunol. 2008, 8, 218-230
237. Doyle, W. J.; Boehm, S.; Skoner, D. P. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy J. Allergy Clin. Inmunol. 1990, 86, 924-935
238. Hey, J.; Aslanian, R.; Bolster, D.; Chapman, R.; Egan, R.; Rizzo, C.; Shih, N.-Y.; Fernandez, Z.; McLeod, R.; West, R.; Kreutner, W. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971 Arzneim-Forsch/Drug Res. 1998, 48, 881-888
239. McLeod, R. L.; Mingo, G. G.; Herczku, C. Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion Am. J. Rhinol. 1999, 13, 391-399
240. Hancock, A. P.; Hodgson, S. T.; Vinader Brugarolas, M.-V.; Washington, M. L. 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-4-{[4-(methylsulfonyl)phenyl] carbonyl Piperazine as Histamine H3 Antagonist. PCT Int. Appl. WO 2006090142, 2006.
241. Gore, P. M.; Hancock, A. P.; Hodgson, S. T.; Kindon, L. J.; Procopiou, P. A. 2-Substituted-4-benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists. PCT Int. Appl. WO 2007122156, 2007.
242. Hodgson, S.; Procopiou, P.; Vinader, B. Preparation of 3-[4-[[4-[4-[[3-(3,3-Dimethyl-1-piperidinyl)propyl]oxy]phenyl]-1-piperidinyl] carbonyl]-1-naphthalenyl]propanoates as Histamine H1 and H3 Antagonists for the Treatment of Inflammatory and/or Allergic Disorders. PCT Int. Appl. WO 2007071691, 2007.
243. McLeod, R. L.; Rizzo, C. A.; West, R. E.; Aslanian, R. G.; McCormick, K. D.; Bryant, M.; Hsieh, Y.; Korfmacher, W.; Mingo, G. G.; Varty, L.; Williams, S. M.; Shih, N.-Y.; Egan, R. W.; Hey, J. A. Pharmacological characterization of the novel histamine H3 receptor antagonist N -(3,5-dichlorophenyl)- N ′-[[4-(1 H -imidazol-4-ylmethyl)phenyl]-methyl]urea (Sch 79687) J. Pharmacol. Exp. Ther. 2003, 305, 1037-1044
244. 1 antagonist chlorpheniramine Bioorg. Med. Chem. Lett. 2003, 13, 1959-1961
245. Arrang, J. M.; Garbarg, M.; Quach, T. T. An agent for the amelioration of vertigo in Menieres syndrome. Betahistine hydrochloride (Serc) JAMA, J. Am. Med. Assoc. 1968, 203, 1122
246. James, A. L.; Burton, M. J. Betahistine for Menieres disease or syndrome Cochrane Database Syst. Rev. 2001, 1 CD001873
247. Anonymous. Treatment of Menieres disease. Br. Med. J. 1970, 614 - 616.
248. Tomita, M.; Gotoh, F.; Sato, T.; Amano, T.; Tanahashi, N.; Tanaka, K.; Yamamoto, M. Comparative responses of the carotid and vertebral arterial systems of rhesus monkeys to betahistine Stroke 1978, 9, 382-387
249. Smith, K.; Meyer, M. Distribution of cardiac output in dogs during intravenous infusion of betahistine Stroke 1976, 7, 257-260
250. Panula, P.; Lintunen, M.; Karlstedt, K. Histamine in brain development and tumors Semin. Cancer Biol. 2000, 10, 11-14
251. Cianchi, F.; Cortesini, C.; Schiavone, N.; Perna, F.; Magnelli, L.; Fanti, E.; Bani, D.; Messerini, L.; Fabbroni, V.; Perigli, G.; Capaccioli, S.; Masini, E. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer Clin. Cancer Res. 2005, 11, 6807-6815
252. Medina, V.; Cricco, G.; Nuñez, M.; Martin, G.; Mohamad, N.; Correa-Fiz, F.; Sanchez-Jimenez, F.; Bergoc, R.; Rivera, E. Histamine-mediated signaling processes in human malignant mammary cells Cancer Biol. Ther. 2006, 5, 1462-1471
253. Sieja, K.; Stanosz, S.; Von Mach-Szczypinski, J.; Olewniezak, S.; Stanosz, M. Concentration of histamine in serum and tissues of the primary ductal breast cancer in women Breast 2005, 14, 236-241 and references therein
254. Medina, V.; Croci, M.; Crescenti, E.; Mohamad, N.; Sanchez-Jimenez, F.; Massari, N.; Nuñez, M.; Cricco, G.; Martin, G.; Bergoc, R.; Rivera, E. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment Cancer Biol. Ther. 2008, 7, 28-35
255. 4 receptors Inflammation Res. 2008, 57 (Suppl. 1) S23-S24
256. Szelag, A. Role of histamine H3-receptors in the proliferation of neoplastic cells in vitro Med. Sci. Monitor 1998, 4, 747-755
257. McCubrey, J.; Milella, M.; Tafuri, A.; Martelli, A.; Lunghi, P.; Bonati, A.; Cervello, M.; Lee, J.; Steelman, L. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors Curr. Opin. Invest. Drugs 2008, 9, 614-630
258. Liu, P.; Cheng, H.; Roberts, T.; Zhao, J. Targeting the phosphoinositide 3-kinase pathway in cancer Nat. Rev. Drug Discovery 2009, 8, 627-644
259. Coruzzi, G.; Poli, E.; Morini, G.; Bertaccini, G. The Histamine H3 Receptor: Pharmacotherapy Targets in Gastrointestinal Disorders. In Drug Development: Molecular Targets for GI Diseases; Gaginella, T. S.; Guglietta, A., Eds.; Humana Press: Totowa, NJ, 1999; pp 239 - 267.
260. Morini, G.; Grandi, D.; Schunack, W. Ligands for histamine H3 receptors modulate cell proliferation and migration in rat oxyntic mucosa Br. J. Pharmacol. 2002, 137, 237-244
261. Grandi, D.; Schunack, W.; Morini, G. Epithelial cell proliferation is promoted by the histamine H3 receptor agonist (R)-α-methylhistamine throughout the rat gastrointestinal tract Eur. J. Pharmacol. 2006, 538, 141-147
262. Pozzoli, C.; Todorov, S.; Schunack, W.; Timmerman, H.; Coruzzi, G.; Poli, E. Role of histamine H3 receptors in control of mouse intestinal motility in vivo and in vitro: comparison with α-2 adrenoreceptors Dig. Dis. Sci. 2002, 47 (5) 1065-1072
263. Poli, E.; Pozzoli, C.; Coruzzi, G. Role of histamine H3 receptors in the control of gastrointestinal motility. An overview J. Physiol. 2001, 95, 67-74
264. Adachi, N. Cerebral ischemia and brain histamine Brain Res. Rev. 2005, 50, 275-286 and references therein
265. 2 action protects hippocampal CA1 neurons by prolonging the onset of the anoxic depolarization in gerbils J. Neurochem. 1996, 67, 2613-2615
266. 2 receptor stimulation in the rat striatum Eur. J. Pharmacol. 2004, 484, 167-173 (Pubitemid 38117207)
267. Sugimoto, K.; Abe, K.; Lee, T. H.; Sakurai, E.; Yanai, K.; Kogure, K.; Itoyama, Y.; Watanabe, T. Histamine depletion in brain caused by treatment with (S)α-fluoromethylhistidine enhances ischemic damage of gerbil hippocampal CA2 neurons Brain Res. 1994, 666, 279-283
268. Irisawa, Y.; Adachi, N.; Liu, K.; Arai, T.; Nagaro, T. Alleviation of ischemia-induced brain edema by activation of the central histaminergic system in rats J. Pharmacol. Sci. 2008, 108, 112-123
269. Marino, M.; Seabrook, G. Treatment of Tremor or Other Movement Disorder with Histamine H3 Inverse Agonists or Histamine H3 Antagonists. PCT Int. Appl. WO 2005097111, 2005.
270. Kostrzewa, R. M.; Nowak, P.; Kostrzewa, J. P.; Kostrzewa, R. A.; Brus, R. Peculiarities of L-DOPA treatment of Parkinsons disease Amino Acids 2005, 28, 157-164
271. 3 receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa-derived extracellular dopamine in dopamine-denervated rat striatum Neurotoxic. Res. 2008, 13, 231-240
272. Seabrook, G.; Koblan, K.; Ho, T. W.-H. Treatment of Stroke with Histamine H3 Inverse Agonists or Histamine H3 Antagonists. PCT Int. Appl. WO 2006058023, 2006.
273. Blackburn, A.; Demattei, J.; Hart, R.; Khulman, Y.; Mesleh, M.; Smith, J. Crystalline Forms of (R)-1-{2-[4′- (3-Methoxy-propane-1-sulfonyl)- biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and Compositions, and Methods Related Thereto. PCT Int. Appl. WO 2008153958, 2008.
274. Folmer, J.; Hunt, S.; Hamley, P.; Wesolowski, S. Preparation of Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression. PCT Int. Appl. WO 2006014134, 2006.
275. Bennani, Y.; Anderson, J.; Wang, J.; Campbell, M. Preparation of Heterocyclic Non-Imidazole Tertiary Amines as Histamine 3 Receptor Inhibitors for the Treatment of Cognitive and Sleep Disorders, Obesity and Other CNS Disorders. PCT Int. Appl. WO 2006004937, 2006.
276. Bennani, Y.; Anderson, J.; Wang, J.; Campbell, M. Preparation of 4-Piperidinol Tertiary Amines as Histamine 3 Receptor Inhibitors for the Treatment of Obesity and Other CNS Disorders. PCT Int. Appl. WO 2006071750, 2006.
277. Hudkins, R.; Josef, A.; Tao, M. Preparation of Pyridizinones as Histamine H3 Inhibitors. PCT Int. Appl. WO 2008013838, 2008.
278. Hipskind, P.; Takakuwa, T.; Jesudason, C.; Gadski, R.; Hornback, W.; Pickard, R.; Beavers, L. Preparation of Phenyl Pyrrolidinylmethylpyrrolidinyl Methanones as Histamine H3 Receptor Agents. PCT Int. Appl. WO 2006107661, 2006.
279. Jesudason, C.; Beavers, L.; Cramer, J.; Dill, J.; Finley, D.; Lindsley, C.; Stevens, F.; Gadski, R.; Oldham, S.; Pickard, R.; Siedem, C.; Sindelar, D.; Singh, A.; Watson, B.; Hipskind, P. Synthesis and SAR of novel histamine H3 receptor antagonists Bioorg. Med. Chem. Lett. 2006, 16, 3415-3418
280. Roche, O.; Nettekoven, M.; Vifian, W.; Sarmiento, R. Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists Bioorg. Med. Chem. Lett. 2008, 18, 4377-4379
281. Roche, O.; Sarmiento, R. A new class of histamine H3 receptor antagonists derived from ligand based design Bioorg. Med. Chem. Lett. 2007, 17, 3670-3675
282. Pierson, P.; Fettes, A.; Freichel, C.; Gatti-McArthur, S.; Hertel, C.; Huwyler, J.; Mohr, P.; Nakagawa, T.; Nettekoven, M.; Plancher, J.-M.; Raab, S.; Richter, H.; Roche, O.; Sarmiento, R.; Schmitt, M.; Schuler, F.; Takahashi, T.; Taylor, S.; Ullmer, C.; Wiegand, R. 5-Hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity J. Med. Chem. 2009, 52, 3855-3868
283. Casara, P.; Chollet, A.; Dhainaut, A.; Bert, L.; Lestage, P.; Lockhart, B. New Azabicyclic, Particularly Octahydrocyclopenta[ c ]pyrrole, Derivatives as H3 Receptor Antagonists, Process for Their Preparation, and Pharmaceutical Compositions Containing Them. PCT Int. Appl. WO 2005089747, 2005.
284. Pringle, W.; Peterson, J.; Xie, L.; Ge, P.; Gao, Y.; Ochterski, J.; Lan, J. Preparation of Thiazole Amides, Imidazole Amides and Related Analogues as Histamine H3 Receptor Modulators. PCT Int. Appl. WO 2006089076, 2006.
285. Gao, Y.; Han, B.; Xu, Y.; Caldwell, T.; Xie, L. Preparation of Piperazinyloxoalkyl Tetrahydroisoquinolines and Related Analogues as Histamine H3 Receptor Modulators. PCT Int. Appl. WO 2007106349, 2007.
286. Lunn, G. Tetrahydronaphthyridine Derivative, Its Preparation, and Its Therapeutic Use. PCT Int. Appl. WO 2007052124, 2007.
287. Diaz, J.; Escribano, B.; Martin, U. Cyclopropylmethanone Derivatives, Particularly (Cyclopropyl)(phenyl)methanone Derivatives, and Their Preparation and Therapeutic Use as H3 Histamine Receptor. PCT Int. Appl. WO 2005037810, 2005.
288. Cole, D. C.; Asselin, M.; Stock, J. R.; Kim, J.-I. Preparation of N -Benzoyl- and N -Benzylpyrrolidin-3-ylamines as Histamine-3 Antagonists. PCT Int. Appl. WO 2007136668, 2007.